MBX Biosciences, Inc. MBX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about MBX Biosciences, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MBX Biosciences, Inc.'s additional paid-in capital?
- MBX Biosciences, Inc. (MBX) reported additional paid-in capital of $686.35M in Q1 2026.
- How has MBX Biosciences, Inc.'s additional paid-in capital changed year-over-year?
- MBX Biosciences, Inc.'s additional paid-in capital increased by 73.0% year-over-year, from $396.75M to $686.35M.
- What is the long-term trend for MBX Biosciences, Inc.'s additional paid-in capital?
- Over 2 years (2023 to 2025), MBX Biosciences, Inc.'s additional paid-in capital has grown at a 1293.9% compound annual growth rate (CAGR), from $3.05M to $593.41M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.